文献速递炎症性肠病

他克莫司栓剂与倍氯米松栓剂治疗难治性溃疡性直肠炎随机试验:无优越性

No Superiority of Tacrolimus Suppositories vs Beclomethasone Suppositories in a Randomized Trial of Patients With Refractory Ulcerative Proctitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-10-11

结论认为两种栓剂对5-ASA难治性UP诱导的临床和内镜应答相当,均为安全有效的治疗选择。

要点

  • 两种栓剂不良事件率无显著差异,均为安全有效的治疗选项。

核心结论

  • 在4周随机对照试验中,他克莫司栓剂与倍氯米松栓剂对5-ASA难治性UP诱导的临床和内镜应答相当。
  • 两组不良事件率无显著差异,他克莫司和倍氯米松栓剂均为5-ASA难治性UP的安全有效治疗选择。

研究设计与样本

  • 随机对照双盲研究,2014年至2017年在荷兰和比利时8家医院进行。

主要发现

  • 不良事件率两组无显著差异。

关键数值与推荐

  • 他克莫司栓剂2 mg每日一次,倍氯米松栓剂3 mg,疗程均为4周。
  • 主要结局为临床应答,定义为Mayo评分下降3分或以上。
  • 次要结局包括临床缓解、内镜应答与缓解、不良事件和生活质量。

临床怎么用

  • 对于5-ASA栓剂难治的溃疡性直肠炎,他克莫司栓剂和倍氯米松栓剂均可作为安全有效的局部治疗选择。
  • 两种栓剂在临床应答、临床缓解、内镜应答及不良事件方面无显著差异,选择时可综合考虑可获得性和患者偏好。

局限性

  • 研究仅评估4周诱导治疗,未报告长期维持疗效和安全性数据。
  • 研究在荷兰和比利时8家医院进行,外推性需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Ulcerative proctitis (UP) refractory to 5-aminosalicylic acid (5-ASA) suppositories is a challenge to treat, often requiring step up to immunomodulator or biological therapy. Topical tacrolimus is effective and safe in patients with refractory UP. However, it is not clear how tacrolimus suppositories fit into in the treatment algorithm of UP. METHODS: We performed a randomized controlled, double-blind study at 8 hospitals in the Netherlands and Belgium from 2014 through 2017. Eighty-five patients with refractory UP (65% women) were randomly assigned to groups given once daily tacrolimus suppositories (2 mg; n = 43) or beclomethasone (3 mg; n = 42) for 4 weeks. The primary outcome was clinical response (decrease in Mayo score of 3 or more). Secondary outcomes included clinical remission, endoscopic response and remission, adverse events and quality of life. Outcomes were compared using Fisher's exact test and Mann-Whitney U test. RESULTS: Proportions of patients with clinical responses were 63% in the tacrolimus group and 59% in the beclomethasone group (P = .812); proportions of patients in clinical remission were 46% and 38%, respectively (P = .638). Proportions of patients with an endoscopic response were 68% and 60% in the tacrolimus group and in the beclomethasone group (P = .636); proportions in endoscopic remission rates were 30% and 13%, respectively (P = .092) Median increases in the inflammatory bowel disease questionnaire score were 18.0 in the tacrolimus group and 20.5 in the beclomethasone group (P = .395). Adverse event rates did not differ significantly between groups. CONCLUSIONS: In a 4-week randomized controlled trial, tacrolimus and beclomethasone suppositories induce comparable clinical and endoscopic responses in patients with UP refractory to 5-ASA. There were no significant differences in adverse events rates. Tacrolimus and beclomethasone suppositories are therefore each safe and effective treatment options for 5-ASA refractory disease. EUDRACT 2013-001259-11; Netherlands Trial Register NL4205/NTR4416.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Lie MRKL, Kreijne JE, Dijkstra G, et al. No Superiority of Tacrolimus Suppositories vs Beclomethasone Suppositories in a Randomized Trial of Patients With Refractory Ulcerative Proctitis. Clin Gastroenterol Hepatol. 2019. PMID: 31610337. doi:10.1016/j.cgh.2019.09.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。